Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of subcutaneous amlitelimab monotherapy in adolescents and adults with moderate-to-severe atopic dermatitis
CTR20241420Phase 3Completed
- Sponsor
- Sanofi
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of amlitelimab in atopic dermatitis (AD), sponsored by Sanofi. Started Apr 2024; status: completed.
02
Drugs
amlitelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20241420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241420.